Prescription Medicine Market in Pakistan Sees Rising Revenues and Fierce Competition

Prescription Medicine Revenues Fuel Industry Rivalry

Pakistan’s pharmaceutical industry is undergoing a major transformation as revenues rise sharply across leading companies, driven by growing demand for prescription medicines and deregulated pricing policies. This surge has intensified competition, with firms racing to capture larger market shares in an increasingly lucrative sector.

Industry analysts note that deregulation of drug prices in 2024 allowed pharmaceutical companies greater freedom to set prices, resulting in significant profit margins. While this has boosted revenues, it has also raised concerns about affordability for patients, as many essential medicines have become more expensive.

The prescription medicine segment remains the largest contributor to revenue growth, with companies investing heavily in marketing, distribution networks, and product diversification. Multinational firms and local manufacturers alike are expanding their portfolios to meet rising demand, particularly in urban centers where healthcare consumption is higher.

Competition is not limited to pricing; firms are also focusing on innovation, branding, and partnerships to strengthen their market positions. Some companies are exploring exports and regional expansion, leveraging Pakistan’s growing pharmaceutical capacity to tap into international markets.

However, the rapid growth has sparked debate over regulatory oversight and consumer protection. The Drug Regulatory Authority of Pakistan (DRAP) currently regulates only life-saving medicines, leaving most prescription drugs subject to market forces. Critics argue that this imbalance allows companies to prioritize profits over patient welfare.

Despite these challenges, the pharmaceutical sector is expected to remain one of Pakistan’s fastest-growing industries in 2026. With revenues climbing and competition intensifying, the market is poised for further consolidation, innovation, and expansion.

For consumers, the trend underscores the importance of transparent pricing mechanisms and stronger healthcare policies to balance industry growth with public affordability. The coming months will reveal whether regulators and policymakers can keep pace with the sector’s rapid evolution.